Evidence map›Paper›PMID 29282225›Full record

Observational studyArchives of disease in childhood2018

Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010-2015.

Godwin Oligbu, Sarah Collins, Carmen Sheppard, Norman Fry, Moira Dick, Allison Streetly, Shamez Ladhani

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Archives of disease in childhood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Safety of ceftriaxone in paediatrics: a systematic review.Archives of disease in childhood · 2020
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sickle cell disease: a comprehensive program of care from birth.Hematology. American Society of Hematology. Education Program · 2019
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Godwin OligbuPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, London, UK.
Sarah CollinsImmunisation, Hepatitis and Blood Safety Department (IHBSD), Public Health England, London, UK.
Carmen SheppardRespiratory and Vaccine Preventable Bacterial Reference Unit (RVPBRU), Public Health England, London, UK.
Norman FryRespiratory and Vaccine Preventable Bacterial Reference Unit (RVPBRU), Public Health England, London, UK.
Moira DickDivision of Health and Social Care Research, King's College London, London, UK.
Allison StreetlyDivision of Health and Social Care Research, King's College London, London, UK.
Shamez LadhaniPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, London, UK.
Public Health England · GBSt George's, University of London · GBKing's College London · GB

Funding

Department of Health
6 · The paper itself

Abstract

objectiveTo describe the clinical presentation, risk factors, serotype distribution and outcomes of invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in the UK.

designProspective national newborn screening for SCD and enhanced national IPD surveillance.

participantsChildren with SCD born in England between 1 September 2010 and 31 August 2014 who developed laboratory-confirmed IPD by 31 December 2015. MAIN OUTCOMES AND MEASURES: Risk of IPD in children with SCD compared with children without SCD during the surveillance period.

resultsEleven children homozygote for haemoglobin S (HbSS) and one double heterozygote for haemoglobin S and C (HbSC) developed IPD. Septicaemia (n=7) and lower respiratory tract infection (n=4) were the main clinical presentations, and serogroup 15 (not present in PCV13) was responsible for 73% (8/11) of cases. Three children with HbSS (27%) died compared with <5% nationally. Children with HbSS had a 49-fold (95% CI 27 to 89, P<0.001) higher risk of IPD compared with their peers without SCD.

conclusionsChildren with SCD remain at increased risk of IPD despite national newborn screening, early penicillin prophylaxis and high pneumococcal vaccine uptake. They are also more likely to die of their infection compared with their peers without SCD. Most IPD cases are now due to serotypes not covered by PCV13. Healthcare professionals need to work more closely with families with SCD and local communities to emphasise the importance of penicillin prophylaxis, explore barriers, allay misguided beliefs and facilitate rapid access to healthcare.

Indexed as

Anemia, Sickle CellCohort StudiesEnglandFemaleHumansInfantInfant, NewbornMaleNeonatal ScreeningOpportunistic InfectionsPneumococcal InfectionsPneumococcal VaccinesPrevalenceRespiratory Tract InfectionsRisk FactorsSepsisPneumococcal Vaccinesinvasive pneumococcal diseasepneumococcal conjugate vaccinerisk factorssickle cell disease

Identifiers

PMID29282225
OpenAlexW2763018496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.